Showing 3991-4000 of 8659 results for "".
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- ZORYVE Cream 0.15% for AD Commercially Available This Weekhttps://practicaldermatology.com/news/zoryve-cream-015-ad-commercially-available-week/2467570/Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild-to-moderate atopic dermatitis in adults and children down to age 6 in the United States, along with a co-promotion agreement with Kowa Pharmaceuticals America, Inc. ZORYVE is a o
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati
- DART Releases New Clinical Guidelines for Nonmelanoma Skin Cancer Treatmenthttps://practicaldermatology.com/news/dart-releases-new-clinical-guidelines-nonmelanoma-skin-cancer-treatment/2467534/The Dermatology Association of Radiation Therapy (DART) has published new clinical guidelines for the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) using image-guided superficial radiation therapy (IGSRT), according to a news release. The guidelines, developed
- Commentary: Beware Impact of TikTok's Algorithm on Dermatological Information Disseminationhttps://practicaldermatology.com/news/commentary-beware-impact-tiktoks-algorithm-dermatological-information-dissemination/2467491/A recent commentary in The Journal of Drugs in Dermatology exploring concerns about the dissemination of dermatological information on T
- Study: Crotoxin Demonstrates Efficacy Against Melanoma with Reduced Toxicityhttps://practicaldermatology.com/news/crotoxin-demonstrates-efficacy-against-melanoma-reduced-toxicity/2467490/A new study in Frontiers in Pharmacology indicated that crotoxin (CTX), a component of snake venom, was associated with antiproliferative effects on melanoma cells. "Melanoma, a highly aggressive skin cancer originating in melanocytes, poses a significant threat due to its metast
- Weekly Cendakimab Dosing Effective in Reducing AD Severityhttps://practicaldermatology.com/news/weekly-cendakimab-dosing-effective-reducing-ad-severity/2467489/New research shows that cendakimab is safe and efficacious at certain dosing levels over a 16-week study period in patients with moderate-to-severe atopic dermatitis (AD). The study authors for the phase 2 trial included 221 adult patients with moderate-to-severe AD from the United States
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent